Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72685
Title:
Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.
Authors:
Schambach, Axel; Schiedlmeier, B; Kühlcke, K; Verstegen, M; Margison, Geoffrey P; Li, Z; Kamino, K; Bohne, J; Alexandrov, A; Hermann, F G; Von Laer, D; Baum, Christopher
Abstract:
The failure of pharmacological approaches to cure infection with the human immunodeficiency virus (HIV) has renewed the interest in gene-based therapies. Among the various strategies that are currently explored, the blockade of HIV entry into susceptible T cells and macrophages promises to be the most powerful intervention. For long-term protection of both of these lineages, genetic modification of hematopoietic stem cells (HSCs) would be required. Here, we tested whether HSCs and their progeny can be modified to express therapeutic levels of M87o, a gammaretroviral vector encoding an artificial transmembrane molecule that blocks fusion-mediated uptake of HIV. In serial murine bone marrow transplantations, efficient and multilineage expression of M87o was observed for more than 1 year (range 37-75% of mononuclear cells), without signs of toxicity related to the transmembrane molecule. To allow enrichment of M87o-modified HSCs after transplant, we constructed vectors coexpressing the P140K mutant of O(6)-methylguanine-DNA-methyltransferase (MGMT-P140K). This clinically relevant selection marker mediates a survival advantage in HSCs if exposed to combinations of methylguanine-methyltransferase (MGMT) inhibitors and alkylating agents. A bicistronic vector mediated sufficient expression of both M87o and MGMT to confer a selective survival advantage in the presence of HIV and alkylating agents, respectively. These data encourage further investigations in large animal models and clinical trials.
Affiliation:
Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany.
Citation:
Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. 2006, 13 (13):1037-47 Gene Ther.
Journal:
Gene Therapy
Issue Date:
Jul-2006
URI:
http://hdl.handle.net/10541/72685
DOI:
10.1038/sj.gt.3302755
PubMed ID:
16541120
Type:
Article
Language:
en
ISSN:
0969-7128
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorSchambach, Axel-
dc.contributor.authorSchiedlmeier, B-
dc.contributor.authorKühlcke, K-
dc.contributor.authorVerstegen, M-
dc.contributor.authorMargison, Geoffrey P-
dc.contributor.authorLi, Z-
dc.contributor.authorKamino, K-
dc.contributor.authorBohne, J-
dc.contributor.authorAlexandrov, A-
dc.contributor.authorHermann, F G-
dc.contributor.authorVon Laer, D-
dc.contributor.authorBaum, Christopher-
dc.date.accessioned2009-07-07T10:31:13Z-
dc.date.available2009-07-07T10:31:13Z-
dc.date.issued2006-07-
dc.identifier.citationTowards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. 2006, 13 (13):1037-47 Gene Ther.en
dc.identifier.issn0969-7128-
dc.identifier.pmid16541120-
dc.identifier.doi10.1038/sj.gt.3302755-
dc.identifier.urihttp://hdl.handle.net/10541/72685-
dc.description.abstractThe failure of pharmacological approaches to cure infection with the human immunodeficiency virus (HIV) has renewed the interest in gene-based therapies. Among the various strategies that are currently explored, the blockade of HIV entry into susceptible T cells and macrophages promises to be the most powerful intervention. For long-term protection of both of these lineages, genetic modification of hematopoietic stem cells (HSCs) would be required. Here, we tested whether HSCs and their progeny can be modified to express therapeutic levels of M87o, a gammaretroviral vector encoding an artificial transmembrane molecule that blocks fusion-mediated uptake of HIV. In serial murine bone marrow transplantations, efficient and multilineage expression of M87o was observed for more than 1 year (range 37-75% of mononuclear cells), without signs of toxicity related to the transmembrane molecule. To allow enrichment of M87o-modified HSCs after transplant, we constructed vectors coexpressing the P140K mutant of O(6)-methylguanine-DNA-methyltransferase (MGMT-P140K). This clinically relevant selection marker mediates a survival advantage in HSCs if exposed to combinations of methylguanine-methyltransferase (MGMT) inhibitors and alkylating agents. A bicistronic vector mediated sufficient expression of both M87o and MGMT to confer a selective survival advantage in the presence of HIV and alkylating agents, respectively. These data encourage further investigations in large animal models and clinical trials.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subjectHaematopoietic Stem Cellsen
dc.subject.meshAIDS Vaccines-
dc.subject.meshAnimals-
dc.subject.meshFlow Cytometry-
dc.subject.meshGene Expression-
dc.subject.meshGene Therapy-
dc.subject.meshGenetic Vectors-
dc.subject.meshHIV Fusion Inhibitors-
dc.subject.meshHIV Infections-
dc.subject.meshHIV-1-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshMale-
dc.subject.meshMice-
dc.subject.meshMice, Inbred C57BL-
dc.subject.meshModels, Animal-
dc.subject.meshO(6)-Methylguanine-DNA Methyltransferase-
dc.subject.meshRetroviridae-
dc.subject.meshTransduction, Genetic-
dc.titleTowards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany.en
dc.identifier.journalGene Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.